Journal of Clinical Oncology
Articles in this Issue
An open-label, single-center phase II trial of mitoxantrone hydrochloride liposome combined with programmed death-1 (PD-1) inhibitors for pretreated recurrent or metastatic nasopharyngeal carcinoma.
6047 Background: Liposomal mitoxantrone (Lipo-MIT) in combination with programmed death-1 (PD-1) inhibitors exhibits poten...
Evaluation of a taxane mRNA-based profile in neoadjuvant therapy across I-SPY2 investigational arms.
597 Background: Neoadjuvant chemotherapy is standard in early-stage breast cancer (eBC), enabling tumor downstaging and tr...
Neoadjuvant chemo-immunotherapy and surgical resection in locally advanced non-small cell lung cancer with N3 lymph node involvement (NEO-SURG).
TPS8127 Background: The emergence of neoadjuvant and peri-operative chemoimmunotherapy in locally-advanced non-small cell...
Camrelizumab combined with concurrent chemoradiotherapy versus chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A retrospective cohort study in central China.
e18083 Background: Immune checkpoint inhibitors have demonstrated efficacy in recurrent or metastatic nasopharyngeal carci...
Neurotoxicity in immune checkpoint inhibitor-associated myositis with elevated soluble IL-2 receptor levels: Novel therapeutic strategies.
e14536 Background: Immune checkpoint inhibitors (ICIs) are used to treat a variety of cancer types, including melanoma, lu...
Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.
7007 Background: At the primary analysis, Mosun-Pola demonstrated superior efficacy versus R-GemOx, with infrequent cytoki...
Efficacy and safety of anlotinib plus docetaxel versus docetaxel monotherapy in advanced non–small cell lung cancer: A systematic review and meta-analysis.
e20734 Background: Docetaxel monotherapy remains a standard second-line treatment for patients with advanced non–small cel...
Impact of <i>BRCA</i> pathogenic variants and novel targeted agents on ovarian reserve measured by anti-Müllerian hormone levels in young women with early breast cancer: A biomarker analysis of the PREFER study.
526 Background: The impact of germline BRCA (g BRCA...
Demographic and clinicopathological factors impacting survival in malignant carcinoid tumors: A SEER database analysis.
e16319 Background: Malignant carcinoid tumors are indolent neuroendocrine neoplasms with generally favorable survival. Whi...
Demographic and molecular landscape of biliary tract cancers in and near Bronx, NY.
e16161 Background: Biliary tract cancers (BTCs), including gallbladder cancer (GBC) and intrahepatic (iCCA), perihilar (pC...
Combining immune checkpoint inhibition and dendritic cell vaccination in advanced pleural and peritoneal mesothelioma: The phase 1b MESOVAX trial.
2548 Background: Mesothelioma (M) remains a rare malignancy with limited therapeutic options. While immunotherapy combinat...
A pathology-based model for postoperative recurrence or metastasis prediction and adjuvant immunotherapy implications of clear-cell renal cell carcinoma: A multi-center, retrospective study.
e16539 Background: Approximately 30% of patients with clear cell renal cell carcinoma experience recurrence after surgery,...
Clinical outcomes with <i>ERBB2</i> gene amplification and activating mutations in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy.
4595 Background: Activating ERBB2 mutations (mut) are associated with improved pathologic response (pCR) to neoadjuvant ch...
Sintilimab (PD-1 antibody) plus gemcitabine and docetaxel (GT) as first-line or later-line therapy in patients with advanced epithelioid sarcoma: A prospective, multicenter, single-arm, phase II clinical study.
11574 Background: Advanced epithelioid sarcoma (ES) responds poorly to conventional chemotherapy, with an objective respon...
Clinical activity and safety of RNK08954 in advanced non–small cell lung cancer (NSCLC) patients with <i>KRAS</i> G12D mutation (NCT06667544).
3006 Background: KRAS G12D is the most prevalent subtype of KRAS mutations across solid tumors. RNK08954 is a potent and s...
Correlation of CT changes, PET response, and histopathologic tumor regression in treated advanced <i>EGFR</i> -mutant NSCLC before disease progression.
8655 Background: Previous studies have examined the correlation between radiologic and pathologic responses using PET, CT,...
Adjuvant DC-CIK plus high-dose interferon-α versus high-dose interferon-α alone in resected stage IIB–IIID melanoma: A propensity score–matched real-world study with long-term follow-up.
e21536 Background: High-dose interferon-α (HD-IFN) has historically served as a standard adjuvant therapy for resected sta...
Dietary changes in head and neck cancer patients pre- and post-chemotherapy and/or radiation therapy.
e24126 Background: Head and neck squamous cancer (HNSCC) patients often face challenges with adequate nutritional intake d...
Real-world feasibility and hematologic toxicity of induction chemotherapy in advanced cervical cancer in a resource-limited setting.
e13634 Background: Induction chemotherapy has reshaped the treatment paradigm for locally advanced cervical cancer (LACC),...
Genomic profiling of diffuse intrinsic pontine glioma in AACR Project GENIE.
e14070 Background: Diffuse intrinsic pontine glioma (DIPG) is an aggressive high-grade glioma, originating in the pons and...
Phase Ib results from the phase Ib/II study of [ <sup>177</sup> Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer.
3010 Background: Most pts with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC) relapse after initial resp...
Prevalence of homologous recombination repair deficiencies in prostate cancer in the Russian Federation.
e17062 Background: Homologous recombination repair (HRR) deficiency represents a frequent and clinically significant molec...
From endotoxin to engineered agonists: A translational strategy to enable TLR4-based immunomodulation in pancreatic cancer.
e14605 Background: Pancreatic ductal adenocarcinoma (PDAC), a lethal malignancy with a dismal 5-year overall survival is h...
Real-world clinical outcomes by HER2 expression in locally advanced/metastatic urothelial carcinoma (la/mUC): Results from the global SGNDV-003 retrospective study.
4562 Background: Approximately 50-80% of patients (pts) with la/mUC have tumors with HER2 protein expression. As HER2-dire...
Association of concurrent COVID-19 infection with in-hospital outcomes among patients hospitalized for head and neck cancer.
e18132 Background: Patients with head and neck cancer (HNC) often have substantial comorbidity and may be particularly vul...